# Long-Term Survival after Curative Resection for Postoperative Dissemination of Pancreatic Ductal Adenocarcinoma: A Case Report

**Authors:** Yoshitaka Shimamaki, Makoto Takahashi, Taku Higashihara, Tatsuya Hayashi, Yasuhiro Morita, Takeshi Azuma, Dai Inoue, Haruka Okada, Masayuki Ohtsuka

PMC · DOI: 10.70352/scrj.cr.24-0022 · Surgical Case Reports · 2025-04-02

## TL;DR

A patient with pancreatic cancer survived for over 13 years after initial surgery and resection of cancer spread, suggesting that removing cancer recurrence might help some patients live longer.

## Contribution

This case report demonstrates long-term survival after resecting disseminated pancreatic cancer, challenging the conventional view that such resections are ineffective.

## Key findings

- The patient survived 13 years and 3 months after initial surgery with no recurrence.
- Resection of disseminated PDAC led to a 5-year recurrence-free period after the second surgery.
- The case suggests that resection of cancer recurrence may benefit selected PDAC patients.

## Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis and high mortality. The prognosis for recurrence after surgery is extremely poor. Resection for disseminations of PDAC is not recommended.

The patient was a 69-year-old woman with a pancreatic tumor that was detected with computed tomography (CT) during a postoperative colon cancer checkup. She was suspected of having pancreatic body cancer without distant metastasis. Distal pancreatectomy with celiac axis resection was performed. Postoperative pathological examination revealed an invasive ductal adenocarcinoma with lymph node metastasis (pT4N1M0, stage III). Postoperatively, she received adjuvant chemotherapy containing gemcitabine and S-1 for 1 year and 4 months, and S-1 monotherapy for 1 year. Six years and 2 months after the initial surgery, her serum carbohydrate antigen 19-9 level elevated, and CT revealed soft tissue in front of the left kidney. Positron emission tomography/CT also revealed high fluorine-18 fluorodeoxyglucose uptake in the tissue. Accordingly, the patient was diagnosed with dissemination of PDAC. The patient was administered chemotherapy with gemcitabine and S-1. One year and 6 months after the diagnosis of dissemination, CT revealed reduction of the nodule. Therefore, we decided to eliminate this dissemination. A left nephrectomy and partial gastrectomy were performed. Histopathological examination confirmed dissemination of PDAC. The patient refused adjuvant chemotherapy. No evidence of recurrence has been observed for 13 years and 3 months since the initial surgery, and 5 years and 1 month since the resection of the dissemination.

This case showed a recurrence of dissemination after radical PDAC surgery, and the patient showed long-term survival without recurrence after dissemination resection. Resection of dissemination may confer long-term survival in selected patients.

## Linked entities

- **Chemicals:** gemcitabine (PubChem CID 60750), S-1 (PubChem CID 1497102)
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184), colon cancer (MONDO:0002032)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11975445/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11975445/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC11975445/full.md

---
Source: https://tomesphere.com/paper/PMC11975445